Expression Pattern of Interferon-γ in Human Leukemic T Cell Lines Following Treatment with Phytoheamagglutinin, phorbol myristate acetate and Lipopolysaccharide

Fatemeh Hajighasemi*, Abbas Mirshafiey

1Department of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran
2Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:
Received: 12.11.2016
Accepted: 30.12.2016

Keywords:
IFN-γ production
Leukemic T-cells
Jurkat cell lines
Molt-4 leukemic cell lines
Phytoheamagglutinin
Phorbol myristate acetate
Lipopolysaccharide

*Corresponding author:
Fatemeh Hajighasemi, PhD;
Address: Department of Immunology, Faculty of Medicine, Shahed University, No. 31, Shahid Abdollahzadeh Street, Keshavarz Blvd., 141565111, P.O.Box : 14155-7435, Tehran, Iran
Tel: +98 21 88964792
Fax: +98 21 8896310
Email: fatimahajighasemi@gmail.com

ABSTRACT

Background: As a T helper type 1 (Th1) derived cytokine, Interferon gamma (IFN-γ) is an important regulator of inflammatory immune responses. Furthermore, IFN-γ plays an essential role in defense against tumors and intracellular pathogens. This study was designed to assess the pattern of IFN-γ production in human leukemic (Jurkat and Molt-4) T cell lines in vitro.

Methods: Jurkat and Molt-4 cells were cultured in whole RPMI-1640 media. The cells were imbedded at a density of 2×10⁶ cell/ml. The cells were stimulated with different concentrations of Phytohemagglutinin (PHA) (2-10 µg/ml), phorbol myristate acetate (PMA) (1-25 ng/ml) or lipopolysaccharide (LPS) (1-4 μg/ml) for activation and cytokine production for 48 hours. Then the cell-conditioned media were used for IFN-γ assay. Analysis of variance (ANOVA) was done for comparing the groups statistically.

Results: PHA and PMA substantially augmented IFN-γ level in human leukemic T cells (Molt-4 and Jurkat) in a dose-dependent manner after 48 hours of incubation compared with untreated control cells, whereas LPS did not have any significant effect on IFN-γ production in human leukemic T cell lines compared with unstimulated cells.

Conclusion: human leukemic Jurkat and Molt-4 T cell lines could potentially produce IFN-γ with different amounts. PHA was a more potent stimulator of IFN-γ production than PMA. Molt-4 cell line could produce more IFN-γ than Jurkat cell line. These cells could be appropriate for studying the mechanisms of action of immunomodulators as well as screening the IFN-γ stimulators/inhibitors.

Introduction

Interferons (IFNs) are well-studied proinflammatory cytokines. Interferon gamma (IFN-γ), as a T helper type 1 (Th1) derived cytokine is an important regulator of inflammatory immune responses. Furthermore, IFN-γ plays an essential role in defense against tumors and intracellular pathogens. There are also crucial roles suggested for IFN-γ in the pathogenesis of numerous diseases such as vitiligo, alopecia areata and Type 1 diabetes. Dysregulation of IFN-γ in some diseases including intracranial aneurysms and kawasaki disease have been demonstrated. Besides decrease of IFN-γ in several diseases such as complicated respiratory viral infections, HIV, cystic fibrosis and asthma has been shown. In addition increased level of IFN-γ in various disorders including type 2 diabetes and inflammatory bowel disease (IBD) has been reported. Immunomodulatory effects of physical activity on IFN-γ has also been revealed. Moreover, the beneficial effects of some drugs such as propranolol, pentoxifylline and...
methotrexate in a number of cardiovascular diseases such as autoimmune myocarditis has been partly attributed to their inhibitory effects on IFN-γ production. Upregulation of IFN-γ by some immunomodulators such as piperine, clinacanthus nutans (a medicinal plant) and leptin had therapeutic effects on immune-compromised tuberculosis, hepatoma and leishmania donovani infections, respectively.

In this study, pattern of IFN-γ production in human leukemic (Jurkat and Molt-4) T-cell lines has been evaluated in vitro.

Materials and Methods

Micorotiter plates, tubes and flasks were purchased from Nunc (Falcon, USA). Fetal calf serum (FCS) got from Gibco (USA). Phytoheamagglutinin (PHA), Phorbol myristate acetate (PMA), Lipopolysaccharide (LPS), penicillin, streptomycin, RPMI-1640 and trypan blue (TB) were purchased from sigma (USA). IFN-γ standard ELISA kit was obtained from R&D company (USA). Human leukemic Molt-4 (NCBI C149) and Jurkat (NCBI C121) T cells were purchased from the National Cell Bank of Iran (NCBI). These cells were retained in RPMI-1640 media complemented by 10% FCS in 5% CO₂ at 37°C.

Cell Culture

The leukemic cells were cultivated in RPMI-1640 media added with 10% FCS, penicillin (100 IU/ml) and streptomycin (100 µg/ml) at 37°C in 5% CO₂. After that the cells were distributed at a concentration of 2×10^6 cells/ml and next treated with different concentrations of PHA (1-10 µg/ml), PMA (5-25 ng/ml) or LPS for 48 hours. The supernatants of cell culture media were removed and used for IFN-γ quantification. Each test was arranged in triplicates.

IFN-γ Test

The extent of IFN-γ produced in cell culture supernatants of leukemic T cells (Molt-4 and Jurkat) was measured with the Quantikine human enzyme-linked immunosorbent assay (ELISA) kits (R&D organizations) as per the manufacturer’s procedures. This test uses the quantifiable sandwich enzyme immunoassay method. Whole RPMI media was used also for control. In order to illustrate the standard curves, human recombinant IFN-γ was used.

Statistical Analysis

IFN-γ measurement in cell-culture medium was done in three diverse tests and the data were specified as mean±standard error of the mean (SEM). Analysis of variance (ANOVA) was used for statistical analysis between groups. P<0.05 was statistically designated as significant. For statistically significant variations, test of multiple comparison of Tukey was performed (5%).

RESULTS

Pattern of PHA-Induced IFN-γ Production in Molt-4 Cells

IFN-γ production was relatively low in unstimulated human leukemic Molt-4 cells, but PHA considerably increased IFN-γ production in Molt-4 cells following 48-hour treatment compared with the control cells dose-dependently (P<0.05, figure 1).

Pattern of PHA-Induced IFN-γ Production in Jurkat Cells

IFN-γ production was very low in unstimulated human leukemic Jurkat cells but PHA markedly increased IFN-γ production in leukemic Jurkat cells subsequent to 48-hour treatment compared with the control cells. The PHA-stimulated IFN-γ production in leukemic Jurkat cells was concentration-dependent (P<0.05, figure 1).

Pattern of PMA-Induced IFN-γ Production in Molt-4 Cells

Unstimulated human leukemic Molt-4 cells produced relatively little amount of IFN-γ, but again PMA considerably increased IFN-γ production in Molt-4 leukemic cells following 48-hour treatment compared with the control cells dose-dependently (P<0.05, figure 2).

![Figure 1](image-url): Effect of PHA on IFN-γ secretion by human leukemic Jurkat and Molt-4 T cell lines. These cells (2×10^6 cells/ml) were cultured in complete RPMI-1640 medium and next were stimulated with various doses of phytoheamagglutinin (PHA) (2-10 µg/ml) for 48 hours. Finally, IFN-γ levels in cell culture media was quantified by ELISA kit. Results are mean ± SEM of three distinctive tests.*P<0.05 was specified significant.
Unstimulated human leukemic Jurkat cells produced very low amounts of IFN-γ but PMA considerably enhanced IFN-γ production in leukemic Jurkat cells following 48-hour treatment compared with the control cells. The PMA-stimulated IFN-γ production in leukemic Jurkat cells was concentration-dependent (P<0.05, figure 2).

IFN-γ production was very low in unstimulated human leukemic Molt-4 cell line and LPS had no effect on IFN-γ production in these cells subsequent to the 48-hour treatment compared with unstimulated control cells (figure 3).

In this study, we found that Jurkat and Molt-4 leukemic T cell lines can produce IFN-γ. We also found that PHA/PMA increase IFN-γ production in above mentioned leukemic cells but LPS did not show any significant effect on IFN-γ production. Different patterns of IFN-γ are expressed in different diseases and different profiles of IFN-γ are produced in response to various stimuli.
antigens. In the present study, PMA, PHA and LPS were used to assess their modulatory effects on IFN-γ production. To our results, induction of IFN-γ mRNA expression by PHA and PMA in Jurkat cells has been shown by Benbernou et al. In their study, Jurkat cells were cultured at 1×10⁶ cells per well and were stimulated simultaneously by PHA (10 µg/ml) and PMA (10 ng/ml). However, Benbernou and colleagues assessed IFN-γ mRNA expression and did not evaluate the level of IFN-γ production. We used 2×10⁶ Jurkat or Molt-4 cell lines and stimulated the cells with different concentrations of PHA (1-10 µg/ml) or PMA (1-25 ng/ml).

According to our results, LPS did not display any significant effect on IFN-γ production in human leukemic cells (Jurkat and Molt-4). Different effects of LPS on IFN-γ production have been determined by different studies. In Kabanov and colleagues’ study, Rhodobacter capsulatus PG LPS stopped IFN-γ production in human whole blood. Their findings are consistent with our results. We assessed the LPS effect on the unstimulated human leukemic cells (Jurkat and Molt-4) and since these cells produced very low amounts of IFN-γ in unstimulated state, therefore we could not conclude that LPS does not have any effect on IFN-γ production. It is suggested to assess the effects of LPS on IFN-γ production on cells stimulated by PHA or PMA. In another study, LPS-stimulated bone marrow mesenchymal stromal cells, showed profoundly decreased IFN-γ gene expression while co-cultured with T lymphocyte.

In our study, PMA increased IFN-γ production in leukemic cells dose-dependently after 48 hours of stimulation. This enhancing effect reached the maximum point at 25 ng/ml of PMA. In accordance to our results, another study showed an increase of IFN-γ production in rat whole blood cells dose-dependently which maximized 6 hours after stimulation with 25 ng/ml PMA. The reason for the discrepancy between our study and the mentioned study was that we used leukemic T-cells incubated with PMA for 48 hours while the mentioned whole blood cells incubated with PMA for 0-10 hours. In addition, consistent with our data, Barten et al. have shown an augmented IFN-γ secretion in healthy whole blood cells stimulated with 25 ng/ml PMA after 5 hours. Moreover, similar to our study, Keski-Nisula and colleagues revealed that PMA increased the excretion of IFN-γ in healthy whole blood cells after 24 hours incubation.

Furthermore, contrary to a previous study which did not observe any significant influence of PHA on the production of IFN-γ in rat whole blood cells, in our study PHA profoundly increased IFN-γ production in human leukemic T cells in a dose-dependent manner after 48 hours of incubation. This discrepancy between that study and ours may be due to the difference in cells which were used, species and incubation time. We used human leukemic T-cells incubated with PHA for 48 hours while in the mentioned study, the researchers used rat whole blood cells incubated with PHA for 0-10 hours. Taken together, according to the results of our study, diverse profiles of IFN-γ are produced in response to various stimulating agents. Also we found that PHA and PMA are potent stimulators of IFN-γ production in human leukemic T-cells. Moreover, PHA was a more potent stimulator of IFN-γ production than PMA. In addition, Molt-4 cell line could produce more IFN-γ than Jurkat cell line. Hence these cells may be appropriate tools to evaluate the mechanism of IFN-γ induction in diseases in which IFN-γ production is dysregulated as well as screening the regulators, stimulators or inhibitors of IFN-γ induction.

Conclusion
According to our data, human leukemic Jurkat and Molt-4 T cell lines could potentially produce IFN-γ with different amounts. PHA was a more potent stimulator of IFN-γ production than PMA. In addition, Molt-4 cell line could produce more IFN-γ than Jurkat cell line. Therefore, these cells possibly will offer proper tools to assess the regulating mechanisms of IFN-γ secretion in diseases in which IFN-γ production is dysregulated as well as screening the regulators, stimulators, or inhibitors of IFN-γ production.

Conflict of Interest: None declared.

References
6. Vashegh H, Jadali Z. Th1/Th2 cytokines in Type


IFN-γ profile in leukemic T cells


